UCB rated at buy by Merrill

Merrill Lynch analyst Erica Whittaker rated UCB at buy on news that the company revealed stronger Cimzia Precise 1 data. At 26 weeks, Cimzia, for the treatment of Crohn's disease, achieved a statistically significant benefit over a placebo in maintenance of remission, making its efficacy comparable to its competitors. Merrill believes Cimzia remains at a disadvantage to Remicade and Humira in terms of clinical experience and marketing. Shares of the Brussels, Belgium, biopharmaceutical company were up €0.97, or 2.51%, at €39.59 on volume of 508,699 shares versus the three-month running average of 411,701 shares. (Brussels: UCB.BR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.